| First Published on Clinicaltrials.gov: |
9/22/2011 |
| Status: |
Not Yet Recruiting |
| ClinicalTrials.gov ID: |
NCT01449578 |
| Sponsor: |
Biogen Idec |
| Purpose: |
This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers.
|
| Phase: |
I |
| Treatment Type: |
Oral tablet at varying doses |
| Trial Type: |
Double Blind, Placebo Controlled |
| Estimated Enrollment: |
63 |
| Eligibility: |
18 to 55 years. Both genders. ONLY healthy volunteers. |
| Details: |
Preclinical and clinical data to date support the exploration of doses of dexpramipexole higher than 150 mg twice daily for their effectiveness in slowing the progression of ALS. Exploration of doses of dexpramipexole higher than 150 mg twice daily is justified by preclinical and clinical data that suggest that higher doses could potentially be more effective in slowing the progression of ALS than the dose of dexpramipexole currently being explored in Phase 3 studies (150 mg twice daily).
This is a Phase 1, single-center, blinded, randomized, placebo controlled, ascending-dose study consisting of 2 parts; Part A (single-ascending dose [SAD]) and Part B (multiple ascending dose [MAD]). The study will explore safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers. |
| Collaborator(s): |
|
| Location(s): |
- Overland Park, Kansas, USA
|
| Primary Investigator: |
Medical Director |
| Contact: |
|
| Trial Protocol as Published on Clinicaltrials.gov: |
|
| ALS Forum: |
|